Skip to content
MMetabolicMomsTHE MAGAZINE FOR MOTHERS ON GLP-1
Menu

Essay

GLP-1 and the Diet Culture We Grew Up With

The mothers starting GLP-1 today were raised on SlimFast and shame. What it means to treat weight as biology after a lifetime of blaming willpower.

By Renée Salazar, Columnista mother on the MetabolicMoms desk, not a treating clinician

Every medical claim in this piece is footnoted to the record it came from — the trial or the FDA label — so you can read the source rather than take the masthead's word for it. No one on this desk is your clinician.

On this page

We were handed a scale and a story

If you are a mother in your thirties or forties, you were raised inside a very specific story about your body: that its size was a report card on your discipline. We grew up with SlimFast for breakfast, fat-free everything, magazines that scored celebrities' beach bodies, and mothers of our own who counted points at the kitchen table. The story had a moral built into it — thin was virtuous, hungry was strong, and if the weight came back, you simply had not wanted it badly enough. Now the same women are being offered a weekly injection that treats weight as a medical condition. The whiplash is real, and it deserves to be named.

It is worth being precise about what the whiplash actually is. It is not the discovery that dieting is hard; we knew that intimately. It is the discovery that the difficulty was never located where we were told it was — that the thing we spent twenty years trying to out-discipline was a signal, and signals can be turned down. That is a genuinely disorienting piece of news to receive in your forties, and no one hands you a way to feel about it.

The story was wrong about the mechanism

The diet culture we inherited got the biology backwards. It told us appetite was a test of character, when appetite is largely a signal — hormonal, insistent, and not especially interested in our willpower. GLP-1 medications make this visible in a way no motivational poster ever could. In a controlled study, semaglutide measurably reduced energy intake and blunted appetite and food cravings; people ate less not because they finally "tried harder," but because the drug quieted the drive to eat1. When you can turn the volume of hunger down with a molecule, it becomes very hard to keep believing the volume was ever a moral failing.

The proof that it was never just willpower

There is an uncomfortable, clarifying piece of evidence hiding in the trial data. In STEP 1, adults on semaglutide lost a mean of 14.9% of their body weight over 68 weeks against 2.4% on placebo2 — but in STEP 4, where everyone first spent 20 weeks on the drug and then half were switched to placebo, the two groups pulled apart hard. The women and men who stayed on it lost a further 7.9% over the next 48 weeks. The ones switched to placebo, eating the same diet, following the same lifestyle program, put 6.9% back on3.

Read that sentence again, because it is the whole argument. Same people. Same instructions. Same effort. The only variable removed was the biology, and the weight came straight back.

Diet culture would read that regain as backsliding, a lapse of resolve at week 30. Medicine reads it correctly: the body defended its old set point the moment the biological help was withdrawn. The same physiology that made the weight come back is the physiology that made it so hard to lose by "eating less and moving more" in the first place. The regain is not the failure. It is the evidence.

Treating weight as biology does not make you weak. It makes you accurate.

The judgment did not disappear. It relocated.

Here is where the essay would like to end and the reporting will not let it. If weight is biology, the moral verdict should evaporate — and it has not. It has moved.

A group of researchers who have spent years studying how people talk about body size pooled their qualitative work with users of these drugs in Brazil, Denmark, Japan, the United States and online communities, and published what they were seeing. Their conclusion is blunt: rather than reducing weight stigma, they write, these drugs may intensify social judgments and inequalities. They are, in their own words, unconvinced that GLP-1 medicines will herald any significant reduction in negative judgment around body weight4.

What replaced the old verdict is a new one, and every mother who has mentioned her prescription at a school gate already knows its vocabulary: cheating, the easy way out. The charge sheet has simply been reissued. You were undisciplined for being heavy; now you are dishonest for treating it.

And the researchers found that this falls unevenly. Women are held to narrower body norms to begin with and are judged more harshly than men as "cheaters" for using the same medication. In partnered households, the work of managing the medication — the ordering, the refills, the scheduling — tends to land on women as well4. Which is to say the new story, like the old one, has been written with mothers in mind.

What "normal" turns out to mean

The most affecting thing in that research is not the stigma finding. It is what participants described wanting.

Not thinness, exactly. Normality. To stop being the thing in the room that gets noticed and adjudicated. One participant, asked what had changed, put it as plainly as it can be put: "I don't feel that… I feel normal." Another described the relief of no longer being a subject of comment — "people just treat you differently… it makes you feel good" — which is a sentence with a great deal of sadness folded into it, because it is an accurate report on how she was being treated before. A third described the quiet in her own head: "it is so delightful when you are used to thinking about food and then getting free from these thoughts"4.

That is a modest thing to want, and it is a damning thing to have to want. None of those women asked to be admired. They asked to be unremarkable.

What changes when you put down the shame

None of this means a GLP-1 is a verdict, or that every mother should be on one — it is a serious medication with real trade-offs and real side effects, and it belongs in a conversation with a clinician, not an advertisement. Nor does the biology argument dissolve the culture; the research is clear that the judgment is following the drug around, and you should expect to meet it.

What it means is subtler and, I think, kinder. You are allowed to stop grading yourself. The mental energy so many of us spent adjudicating our own hunger — the invisible ledger of everyone's meals — was energy the diet culture taxed and never repaid. You may still get the word cheating at a birthday party, and there is no argument that will land in that moment. But you do not have to say it to yourself in the bathroom mirror, and that is the part that was doing the real damage. Treating weight as biology does not make you weak. It makes you accurate.

Frequently asked questions

Does taking a GLP-1 mean I lack willpower?

No. Appetite is driven substantially by hormonal signals, not character. In the STEP 4 trial, people who stayed on semaglutide lost a further 7.9% over 48 weeks while those switched to placebo — same diet, same program — regained 6.9%. The only variable removed was the medication, which is evidence the difficulty was biological, not a failure of resolve.

Do GLP-1 medications reduce weight stigma?

The researchers studying this do not think so. A 2025 synthesis of qualitative work with users across Brazil, Denmark, Japan, the United States and online communities concluded these drugs may intensify social judgment rather than reduce it, with use widely labeled 'cheating' or 'the easy way out' — and women judged more harshly than men for the same prescription.

Where this leaves you

References

  1. Friedrichsen M, et al. (2021). The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes, Obesity and Metabolism. https://pubmed.ncbi.nlm.nih.gov/33269530/
  2. Wilding JPH, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. https://pubmed.ncbi.nlm.nih.gov/33567185/
  3. Rubino D, et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity (STEP 4). JAMA. https://pubmed.ncbi.nlm.nih.gov/33755728/
  4. Jensen SD, Gualano B, Andreassen P, Scagliusi FB, SturtzSreetharan C, Brewis A (2025). Beyond the prescription: Global observations on the social implications of GLP-1 receptor agonists for weight loss. PLOS Global Public Health. https://pubmed.ncbi.nlm.nih.gov/41452858/

Reported, not prescribed. Everything on this page is journalism and general education — not a diagnosis, a treatment plan, or a recommendation to start or stop any medication. Your history, hormones, and pregnancy plans are yours alone; only a licensed clinician who knows them can advise you. Talk to one before you act on anything you read here.